



Oventus: Innovators in Sleep Apnoea Treatment

May 2017



Disclaimer

1. The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Oventus Medical Limited ACN 608 393 282 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation and particular needs of any particular investor.
2. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk.
3. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation.
4. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed.
5. Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.

Oventus Overview

Oventus' core technology is the 3D Printed patented airway

Oventus Airway Technology is the **only** technology that addresses resistance and obstructions at all levels of the airway enhancing airflow and enabling improved treatment outcomes

This technology has been shown to make both oral appliance therapy and CPAP therapy more effective and/or better tolerated

This technology is an enabling technology that can be deployed in competition with or in conjunction with existing technologies

Oventus Airway Technology can be incorporated into both oral appliances and CPAP improving patient outcomes, negating the need for surgical intervention and providing diagnostic and monitoring solutions in one platform – the NEXUS in the treatment of OSA



Oventus O₂Vent appliances: it's all about the airway



Addresses obstruction

Reduces airway collapsibility

Treats mild to severe apnoea

**Improved compliance
and outcomes**



OVENTUS[®]



Excellent results
for snoring



80% elimination



>95% reduced to a
level that is acceptable
to their partner



Low ongoing cost and
faster manufacturing

Sleep apnoea is a global health & economic issue

Sleep apnoea effects at least 4% of the population



**Sleep
apnoea**



**Major
contributor:
Obesity**



**Result:
Lack of
quality sleep**



**Key indicator:
Snoring**

Immediate effects

fatigue, low energy, daytime sleepiness

Long-term impact

diabetes, stroke, heart disease, high blood pressure etc...

Currently, sleep clinicians are limited in their capacity to treat using oral appliances

Without Oventus



Patient goes to GP for referral to Sleep Clinician (in Australia)



Sleep Clinician prescribes a sleep test



Oral device (mild to moderate)

Patient is sent to **dentist** for fitting and administration due to complexity of care



CPAP (moderate to severe)

Patient will often be directed towards **CPAP** due to high cost, complexity of delivery and question over success rates of current oral devices



Follow up sleep testing may be recommended

Existing treatments

Oral appliances

However, 50% of patients do not adhere to proper use within a year

- Question over cost vs reward
- Nasal resistance in > 50%
- Complex Diagnosis & treatment



Oral appliances

CPAP

The “Gold Standard” treatment

However, 50% of patients do not adhere to proper use within a year

- Nasal obstruction an issue
- Mask-related issues
- High pressure
- Air leakages and noise
- Lack of portability e.g travelling or camping



CPAP

Limited patient outcomes

Low cost trial devices will allow patients to be immediately treated

With Oventus



**Symptom:
Snoring**



Patient goes to
Pharmacy or GP



Purchase trial
OTC device
with monitoring
capability



Receives
immediate
feedback



**Symptom:
Sleep apnoea**



Patient goes to
GP for referral to
Sleep Clinician
(in Australia)



Sleep Clinician
prescribes a
sleep test



Diagnosis and treatment
recommendation: appliance
with or without PAP



**Oventus overcomes
key issues:**

Cost Risk Time

In the future



Boil & Bite: delivered on
spot, with or without CPAP

Testing and feedback
in real time

Custom made applications

Patient can order a longer
lasting, custom-made device
delivered through dentist

However, up to 80% of patients are still out of care



Surgery

UPPP – 33%

RFA – 34%

Maxillo-Mandibular Advancement – 87%

Multilevel surgery – 56%



CPAP Devices

83%



Oral Devices

55%

Why?



Risk of failure



Monitoring issues



Lack of awareness



Time & cost restrictions



Reliance on dentists



Nasal resistance



Oral appliances



CPAP

Oventus O₂Vent + CPAP

A sleep apnoea management platform. A paradigm shift that combines CPAP with normal breathing




Low cost



Improved compliance, efficacy and feedback



Monitoring anytime anywhere



Oral appliances



CPAP



Clinician-managed solutions

Our innovative product portfolio meets the growing opportunity to bridge the gap between clinicians and dentists



Clinicians only

CPAP

Products include:

PAP connection
+ PAP pump

Clinicians and Dentist

Trial device
& Sleep Tests

Products include:


B&B,
Level 3 sleep test
+ APP

Dentists

Custom Appliances

Products include:


O2Vent Mono,
O2Vent T, O2Vent
Wings, others in
development



Distribution channels


Sleep clinicians for the trial appliances and PAP connection

Dentists have been the focus for the initial bespoke oral appliances



Market Outlook

Current sleep treatment market has been growing at 15-20% CAGR Historically



Anti-snoring and sleep apnoea device market including CPAP (\$US Million)

Strong IP position



Core patent issued in Aust & National phase overseas:

WO 2012/155214
Inventor
Dr Chris Hart
Title: Breathing assist device

National phase: WO/2015/149127A1:

Breathing Assist Device covers numerous design aspects and additive manufacturing

PCT: WO/2017/020079A1:

Breathing Assist Device with Tongue Retaining Device

PCT: AU2017050271 CN 2016211252195

Titratable design with an airway – allows lower jaw adjustment by the patient

PROV: AU2016904167:

PAP connectors to the Oventus airway

PROV: AU 2016904924

Compliance and airflow sensors



Multiple domain names registered



Trademarks advancing according to Madrid protocol

Progress over the past year has been strong




Our aim: to be cash positive by 2019

Key Success Measures


Global roll out through partnerships

Complete product range with expanded independent clinical evidence, with KOLs

Scaled manufacturing for a broader customer base



Looking ahead






Finances

	Details
Cash on hand (31/3/17)	\$5,000,000
Revenue FY to date	\$347,000
Burn rate January to March 2017 quarter	\$1,500,000

Capital Structure

	Details
Shares on Issue	72.0m
Options	3.84 m
Price (8/5/17)	\$0.44
Market Cap	\$31.7m





Be a part of this revolution in sleep apnoea treatment



Neil Anderson

Managing Director & Chief Executive Officer

neil@oventus.com.au

0403 003 475

Dr Chris Hart

Clinical Director & Founder

chris@oventus.com.au

0409 647 496



Board and Management



Dr Mel Bridges
Non-executive Chairman

Extensive experience as an Executive and Company Director in healthcare, agricultural technology, drug development, pathology, diagnostics and medical devices

Has successfully raised in excess of \$300M investment capital in the healthcare/biotech sector and been directly involved in over \$1B in merger and acquisition and related transactions



Ms Sue MacLeman
Non-executive Director

Very broad commercial experience in multiple companies – currently CEO of the Medical Technology and Pharmaceutical Industry Innovation Growth Centre

Underpinned by graduate qualifications in pharmacy and post graduate qualifications in corporate governance, commercial law, business administration and marketing



Mr Steve Denaro
Company Secretary

Experienced Company Secretary and Chief Financial Officer of various public companies and with major chartered accountancy firms in Australia and the UK

Bachelor of Business in Accountancy, Graduate Diploma in Applied Corporate Governance and is a member of the Institute of Chartered Accountants in Australia & New Zealand

Board and Management (cont.)



Dr Chris Hart
Clinical Director

Experienced dentist with extensive business experience

Heads up clinician engagement for the delivery of the Oventus appliances

Inventor of the core design

Executive Director



Mr Neil Anderson
Managing Director & Chief Executive Officer

Experienced CEO, project manager, materials scientist and entrepreneur

In-depth skills and knowledge of medical device commercialisation – in the field for over 30 years

Has managed the R&D, manufacturing process and regulatory

Executive Director



Ms Elise Hogan
VP of Sales and Marketing

Elise has over 20 years' experience as a medical device executive leading the sales, marketing and commercialisation teams in Australia, New Zealand, UK, and Asia

Previously Vice President, Oceania and Asia for LivaNova and was responsible for the establishment and growth of the Australian subsidiary, and numerous product launches and geographical expansion throughout Asia and Australia/New Zealand